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Evaluation of a digitally-enabled care pathway for acute
kidney injury management in hospital emergency admissions
Alistair Connell 1,2, Hugh Montgomery1, Peter Martin3, Claire Nightingale3,4, Omid Sadeghi-Alavijeh5, Dominic King2,
Alan Karthikesalingam2, Cian Hughes2, Trevor Back2, Kareem Ayoub2, Mustafa Suleyman2, Gareth Jones5, Jennifer Cross5,
Sarah Stanley5, Mary Emerson5, Charles Merrick5, Geraint Rees6, Chris Laing5,7 and Rosalind Raine3
We developed a digitally enabled care pathway for acute kidney injury (AKI) management incorporating a mobile detection
application, specialist clinical response team and care protocol. Clinical outcome data were collected from adults with AKI on
emergency admission before (May 2016 to January 2017) and after (May to September 2017) deployment at the intervention site
and another not receiving the intervention. Changes in primary outcome (serum creatinine recovery to ≤120% baseline at hospital
discharge) and secondary outcomes (30-day survival, renal replacement therapy, renal or intensive care unit (ICU) admission,
worsening AKI stage and length of stay) were measured using interrupted time-series regression. Processes of care data (time to AKI
recognition, time to treatment) were extracted from casenotes, and compared over two 9-month periods before and after
implementation (January to September 2016 and 2017, respectively) using pre–post analysis. There was no step change in renal
recovery or any of the secondary outcomes. Trends for creatinine recovery rates (estimated odds ratio (OR)= 1.04, 95% conﬁdence
interval (95% CI): 1.00–1.08, p= 0.038) and renal or ICU admission (OR= 0.95, 95% CI: 0.90–1.00, p= 0.044) improved signiﬁcantly at
the intervention site. However, difference-in-difference analyses between sites for creatinine recovery (estimated OR= 0.95, 95% CI:
0.90–1.00, p= 0.053) and renal or ICU admission (OR= 1.06, 95% CI: 0.98–1.16, p= 0.140) were not signiﬁcant. Among process
measures, time to AKI recognition and treatment of nephrotoxicity improved signiﬁcantly (p < 0.001 and 0.047 respectively).
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INTRODUCTION
Acute kidney injury (AKI) is a sudden reduction in kidney function,
identiﬁed and classiﬁed by a rise in serum creatinine concentra-
tion or reduction in urine output.1 Diverse factors contribute to its
pathogenesis, including hypovolaemia, sepsis, nephrotoxicity,
renal tract obstruction, cardiac or liver dysfunction and primary
renal diseases (e.g., glomerulonephritis or interstitial nephritis). AKI
affects up to 15% of UK adult hospital admissions,2,3 with 50% of
cases occurring on presentation in those admitted via the
emergency department (ED).4,5 AKI causes ﬂuid overload and
metabolic derangement, and may adversely affect other organ
systems.6 It is associated with a need for prolonged hospitalisa-
tion,7 renal replacement therapy8 and high dependency care,9 and
with greater in-hospital mortality rates.10 Lifetime risk of chronic
and end-stage kidney disease is raised in AKI survivors,11
contributing signiﬁcantly to their global prevalence.12 Excess
costs associated with AKI to the National Health Service (NHS) in
England exceed £1 billion annually.3
AKI management involves recognition, supportive care, therapy
directed at the underlying cause, monitoring, renal replacement
therapy (if required), appropriate follow-up and interventions to
reduce recurrence6. Because prompt AKI identiﬁcation might
support timely and effective treatment, NHS England mandated
the embedding of an AKI detection algorithm—The NHS Early
Detection Algorithm (NHSEDA; Supplementary Fig. 1)—in the
laboratory information management systems of English NHS
hospitals.13 Cases so identiﬁed must now be notiﬁed to clinicians
in results viewing systems.
Direct real-time communication of AKI cases (‘e-alerts’) might be
expected to expedite effective treatments. However, in a rando-
mised clinical trial, automated AKI e-alerts delivered via mobile text-
messaging yielded no improvement in care processes (rates of
renal consultation, contrast and other nephrotoxin administration)
or clinical outcome (a composite endpoint of relative maximum
change in creatinine, dialysis and death),14 perhaps because
processes of care were not formally modiﬁed. Furthermore,
delivering early and specialist care beneﬁts outcomes in other
acute conditions,15,16 and the UK National Institute for Health and
Care Excellence (NICE) recommends that all severe AKI (stage 3)
should receive specialist nephrology review, while advocating that
the putative beneﬁts of such action be evaluated.17
We sought to address these issues through the design and
implementation of a novel AKI care pathway in which a specialist
response team used a mobile AKI detection and management
application and delivered a care protocol. We evaluated the
impact of this intervention on patient care and outcomes. Here,
we report these for patients presenting acutely to a hospital ED
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who had AKI on arrival. Results relating to patients developing AKI
during the course of their hospital stay, and results from
qualitative and economic analyses, will be published separately.
RESULTS
Evaluation cohort
The pathway was implemented at the Royal Free Hospital (RFH), a
large central London (UK) tertiary referral hospital. The comparator
site (which did not receive the digitally enabled care pathway)—
Barnet General Hospital (BGH)—is a district general hospital and
also part of the Royal Free London NHS Foundation Trust (RFLFT).
At the intervention site (RFH), clinical validation of the 4392 and
2254 AKI alerts during pre-deployment (May 2016 to January
2017) and post-deployment (May to September 2017) phases,
respectively, yielded 1760 and 919 AKI episodes in each phase,
with 755 (42.9%) and 439 (47.8%) located in the ED. In the pre-
deployment and post-deployment phases at BGH, clinical valida-
tion of the 2866 and 1364 alerts, respectively, yielded 1669 and
772 AKI episodes, with 1015 (60.8%) and 422 (54.7%) being
located in the ED.
Table 1 summarises sociodemographic and clinical character-
istics of patients producing AKI alerts in the ED at both evaluation
sites and time periods. RFH patients were younger (median 71 vs.
78 years, p < 0.001), less deprived (p < 0.001) and less likely to be
white (65.6 vs. 78.6%, p < 0.001) than at BGH. RFH patients had
signiﬁcantly more comorbidity (median and interquartile range
(IQR) Charlson score 4.5 (IQR 3.0–7.0) vs. 4.0 (IQR 3.0–6.0), p <
0.001) and signiﬁcantly more severe AKI (p < 0.001). The propor-
tion of patients with pre-existing renal disease was also higher
(34.1 vs. 19.8%, p < 0.001). Comparing the pre- and post-
intervention cohorts, there were some signiﬁcant differences
within each evaluation site. In the post-intervention period at RFH,
patients were younger (median age 72 vs. 69 years, p= 0.003). At
BGH, patients in the post-intervention period were less likely to be
white (80.8 vs. 73.2%, p= 0.030), and had a signiﬁcantly higher
burden of co-morbid disease (p < 0.001). At both RFH (37.8 vs.
32.0%, p= 0.047) and BGH (23.2 vs. 18.4%, p= 0.045), patients in
Table 1. Sociodemographic and clinical characteristics of patients producing AKI alerts in the Emergency Department
Variable Hospital site/time period P value
RFH pre RFH post BGH pre BGH post RFH pre
vs. RFH
post
BGH pre
vs. BGH
post
All RFH
vs. all
BGH
No. of AKI alerts 766 439 1015 422
Alert severity AKI1 455 (59.4%) 272 (62.0%) 658 (64.8%) 289 (68.5%) 0.681 0.322 <0.001
AKI2 161 (21.0%) 86 (19.6%) 210 (20.7%) 83 (19.7%)
AKI3 150 (19.6%) 81 (18.5%) 147 (14.5%) 50 (11.8%)
Male 417 (54.4%) 244 (55.6%) 521 (51.3%) 219 (51.9%) 0.747 0.890 0.092
Median age in years (IQR) 72.00 (59.00–83.50) 69.00 (55.00–82.00) 78.00 (64.00–87.00) 78.00 (67.00–86.00) 0.003 0.793 <0.001
Ethnicity White 509 (66.4%) 280 (63.8%) 820 (80.8%) 309 (73.2%) 0.739 0.030 <0.001
Black or Black
British
68 (8.9%) 46 (10.5%) 31 (3.1%) 19 (4.5%)
Asian or
Asian British
79 (10.3%) 53 (12.1%) 75 (7.4%) 46 (10.9%)
Mixed 10 (1.3%) 6 (1.4%) 4 (0.4%) 3 (0.7%)
Other ethnic
groups
100 (13.1%) 54 (12.3%) 85 (8.4%) 45 (10.7%)
Index of
multiple
deprivation
Quintile 1
(least
deprived)
180 (23.5%) 95 (21.6%) 76 (7.5%) 39 (9.2%) <0.001 0.898 <0.001
Quintile 2 191 (24.9%) 100 (22.8%) 212 (20.9%) 88 (20.9%)
Quintile 3 183 (23.9%) 96 (21.9%) 315 (31.0%) 122 (28.9%)
Quintile 4 169 (22.1%) 112 (25.5%) 305 (30.0%) 112 (26.5%)
Quintile 5
(most
deprived)
38 (5.0%) 28 (6.4%) 102 (10.0%) 58 (13.7%)
Unknown 5 (0.7%) 8 (1.82%) 5 (0.5%) 3 (0.7%)
Charlson score 0 48 (6.3%) 45 (10.3%) 78 (7.7%) 16 (3.8%) 0.619 <0.001 <0.001
1 45 (5.9%) 21 (4.78%) 73 (7.2%) 19 (4.5%)
2 77 (10.1%) 36 (8.2%) 84 (8.3%) 44 (10.4%)
3 93 (12.1%) 43 (9.79%) 137 (13.5%) 57 (13.5%)
4 130 (17.0%) 60 (13.7%) 307 (30.2%) 91 (21.6%)
≥5 373 (48.7%) 234 (53.3%) 336 (33.1%) 195 (46.2%)
Pre-existing renal disease
present
245 (32.0%) 166 (37.8%) 187 (18.4%) 98 (23.2%) 0.047 0.045 <0.001
AKI acute kidney injury, IQR interquartile range, RFH Royal Free Hospital, BGH Barnet General Hospital, pre May 2016 to January 2017, post May 2017 to
September 2017
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the post-intervention period had a higher burden of pre-existing
renal disease.
Primary outcome
We found no evidence for a step change in renal recovery rate
following the intervention at RFH. The estimated odds ratio (OR)
for the intervention step change was 1.03 (95% conﬁdence
interval (95% CI): 0.56–1.87), which was not signiﬁcantly different
from 1 (p= 0.932). There was also no evidence for a difference in
step change of recovery rate between RFH and BGH (estimated
OR= 1.10, 95% CI: 0.48–2.53, p= 0.830). Estimates from the
segmented regression analysis of weekly renal recovery rate which
relate to the research hypothesis are shown in Table 2; all model
coefﬁcients are shown in Supplementary Table 2. The data and
model predictions are illustrated in Fig. 1.
The model estimated a statistically signiﬁcant change in the
trend of renal recovery rates at RFH (estimated OR= 1.04, 95%
CI:1.00–1.08, p= 0.038), indicating that the trend in the interven-
tion period at RFH was stronger in the direction of higher recovery
rates, compared to the pre-intervention period. However, we
found no signiﬁcant difference in the trend change between sites
(estimated OR= 0.95, 95% CI: 0.90–1.00, p= 0.053). There may
have been a trend towards decreasing recovery rates at RFH in the
pre-intervention period, which may have been reversed in the
intervention period (Fig. 1 and Supplementary Table 2). Model
estimates from the sensitivity analysis controlling for differences in
casemix do not differ substantially from the primary analysis
model estimates (Supplementary Table 3). However, in the
sensitivity analysis, none of the four effects of interest are
statistically signiﬁcant.
Secondary clinical outcomes
Of the 20 coefﬁcients of interest for secondary outcomes, 11 had
estimated odds ratios suggesting a beneﬁcial effect of the
intervention. The only statistically signiﬁcant ﬁnding was the
estimate for the effect of the intervention on the trend change in
Table 2. Results of segmented regression analyses
Renal recovery Mortality
β P value OR 95% CI β P value OR 95% CI
Intervention 0.03 0.932 1.03 (0.56–1.87) −0.82 0.055 0.44 (0.19–1.01)
Site × intervention 0.09 0.830 1.10 (0.48–2.53) −0.66 0.273 0.52 (0.16–1.67)
Time × intervention 0.04 0.038 1.04 (1.00–1.08) −0.05 0.104 0.95 (0.90–1.01)
Time × site × intervention −0.05 0.053 0.95 (0.90–1.00) 0.04 0.382 1.04 (0.95–1.13)
Progression of AKI stage Admission to ICU/renal unit
β P value OR 95% CI β P value OR 95% CI
Intervention 0.19 0.783 1.22 (0.30–4.89) 0.23 0.568 1.26 (0.57–2.79)
Site × intervention −0.52 0.596 0.59 (0.08–4.08) 0.33 0.597 1.40 (0.40–4.81)
Time × intervention −0.07 0.162 0.93 (0.83–1.03) −0.05 0.044 0.95 (0.90–1.00)
Time × site × intervention 0.05 0.467 1.05 (0.92–1.22) 0.06 0.140 1.06 (0.98–1.16)
Readmission at 30 days RRT use at 30 days
β P value OR 95% CI β P value OR 95% CI
Intervention 0.47 0.204 1.59 (0.78–3.28) −0.68 0.405 0.51 (0.10–2.50)
Site × intervention −0.54 0.334 0.58 (0.19–1.73) −17.24 0.996 0.00 (0.00–Inf )
Time × intervention 0.03 0.195 1.03 (0.99–1.08) −0.11 0.057 0.90 (0.80–1.00)
Time × site × intervention 0.02 0.552 1.02 (0.95–1.10) 0.07 1.000 1.07 (0.00–476.75)
The coefﬁcient intervention provides an estimate of the difference in outcome between the intervention period and the pre-intervention period at RFH. The
two-way interaction site × intervention provides an estimate of the difference-in-difference between the two hospital sites. The two-way interaction time ×
intervention provides an estimate of the difference in outcome trend over time in the intervention period compared to the pre-intervention period at RFT. The
three-way interaction time × site × intervention provides an estimate of the difference-in-difference in the trend between the sites
OR odds ratio, CI conﬁdence interval, AKI acute kidney injury, ICU intensive care unit, RRT renal replacement therapy
Fig. 1 Weekly recovery rate at RFH and BGH before and after
implementation of the care pathway. RFH Royal Free Hospital, BGH
Barnet General Hospital. Individual data points reﬂect the rate of
each outcome for a single week. Solid lines indicate ﬁtted values
from the modelling functions
A. Connell et al.
3
Scripps Research Translational Institute npj Digital Medicine (2019)    67 
admission to intensive care unit (ICU) or renal units during RFH
admission (estimated OR= 0.95, 95% CI: 0.90–1.00, p= 0.044).
However, we found no signiﬁcant difference in the trend change
between sites (OR= 1.06, 95% CI: 0.98–1.16, p= 0.140). Overall,
there was therefore no compelling evidence for an effect of the
intervention on these secondary outcomes. Estimates of interest
from the segmented regression analyses of secondary outcomes
are shown in Table 2. All model coefﬁcients are shown in
Supplementary Table 2. The data and model predictions are
shown in Supplementary Figs 5 to 9.
At RFH, the median (and IQR) time to renal recovery was 2 days
(IQR 1–12 days) before and 3 days (IQR 1–13.25 days) after the
introduction of the intervention (p= 0.128). At BGH, the median
(IQR) time to renal recovery was 2 days (1–9 days) before and
2 days (1–5 days) after the intervention respectively (p < 0.001).
Using competing risk analyses, a signiﬁcant reduction in length of
stay was demonstrated at both RFH (p= 0.024) and BGH (p <
0.001) after the RFH implementation period (Supplementary Figs
10 and 11).
Processes of care
For alerts produced for patients in the ED during the intervention
period at RFH, the median (IQR) time from alert generation to alert
review by a specialist was 11.50 (IQR 1.00–58.25) min.
Clinical notes for 540 episodes of clinician-conﬁrmed AKI were
reviewed. Of these, 32 were removed from the ﬁnal analysis due
to incomplete data, leaving 266 and 242 in the pre- and post-
implementation periods, respectively. Before and after the
introduction of the care pathway, the number of unrecognised
AKI cases reduced signiﬁcantly from 33 to 8 (12.4% to 3.3%, p <
0.001). Following pathway implementation, time from ED registra-
tion to AKI recognition also reduced signiﬁcantly (log-rank test p <
0.001, Fig. 2).
To determine whether improvements in the time to AKI
recognition related to changes in the ED admission pathway at
RFH, the times of all alerts generated for patients in ED at RFH
during the calendar-matched time periods were compared. There
were no signiﬁcant differences in the time at which creatinine
tests were released by the laboratory at RFH; the median (IQR)
time from entry to ED to AKI alert generation was 113.5
(81.3–155.2) and 107.3 (77.3–141.4) min before and after the
introduction of the intervention, respectively (p= 0.263). These
data suggest improvement in the recognition of AKI related to
results viewing in-app, interpretation and timely documentation.
Timeframes for treatment of each of the main causes of AKI,
before and after pathway implementation, are detailed in Table 3.
At RFH, implementation was associated with a signiﬁcant
reduction in the time to treatment of nephrotoxins (median time
to treatment 207.5 vs. 145.0 min, p= 0.047). Implementation was
associated with faster treatment in patients admitted with sepsis-
related AKI and those with obstruction (median times to treatment
114.0 vs. 100.0 min, p= 0.288, and 268.0 vs. 224.0 min, p= 0.498,
respectively), although in both cases the differences were not
statistically signiﬁcant.
DISCUSSION
We successfully implemented a digitally enabled AKI care pathway
and evaluated its impacts using interrupted time-series analysis.
There was no evidence of a step change in primary and secondary
outcomes at the intervention site following implementation. There
was a signiﬁcant improvement in outcome trend in renal recovery
and renal unit/ICU admission at the intervention site, although this
trend change was not statistically signiﬁcantly different from that
observed at the comparator site. Pathway implementation was
associated with signiﬁcant improvement in the reliability of AKI
recognition, a reduction in the timeframe in which recognition
occurred, and a reduction in the timeframe in which adjustment of
potentially nephrotoxic medications occurred for this group.
Observed improvements in the time to treatment for sepsis and
renal tract obstruction were not statistically signiﬁcant.
Our implementation of the digitally enabled care pathway
fulﬁlls NHS England’s objective to achieve earlier diagnosis and
Fig. 2 Time to recognition of acute kidney injury (AKI).
Kaplan–Meier curves for recognition of AKI after entry to the
Emergency Department, before and after the implementation of the
care pathway. The vertical dashed line represents the median time
of creatinine result release across both time periods
Table 3. Timeframes for the treatment of AKI at RFH
Time period Number of patients treated Median (IQR) time to treatment (min) P value
Sepsis, infection and hypovolaemia Before implementation 223 114.0 (50.0–216.5) 0.288
After implementation 196 100.0 (45.0–195.2)
Nephrotoxicity Before implementation 28 207.5 (145.8–313.5) 0.047
After implementation 43 145.0 (105.5–224.5)
Obstruction Before implementation 27 268.0 (186.5–632.5) 0.498
After implementation 31 224.0 (114.5–875.5)
Primary renal disease Before implementation 8 515.5 (203.8–1295.5) 0.345
After implementation 6 1087.0 (537.0–1602.0)
AKI acute kidney injury, RFH Royal Free Hospital, IQR interquartile range
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more reliable treatment through the use of the NHSEDA. Our
evaluation also helps to clarify why e-alerting alone might fail to
improve outcomes;14 we demonstrate the need to consider the
organisational as well as the technical aspects of digital
interventions by coupling the alerting system to speciﬁc manage-
ment pathways. However, we were unable to establish deﬁnitively
whether early specialist input via the digitally enabled pathway
improves outcome. There are several possible explanations for
these ﬁndings.
Firstly, clinical outcome may not be readily modiﬁable for ED
patients at the point of AKI diagnosis. Creatinine-based AKI
diagnosis necessarily occurs some time after an insult18 and, for
ED patient cohorts, both insult and renal injury may also have
been established some considerable time before admission.
Secondly, baseline processes and outcome at the intervention
site were already good: 30-day mortality for pre-intervention
patients at RFH was 15.0%, compared to a nationally reported 30-
day mortality for all AKI reported to the Renal Registry from April
2016 to September 2017 of 18.1%.19 Thirdly, demonstrable
process improvement may have been insufﬁciently impactful on
the outcomes considered here. Fourthly, the lack of difference in
changes in outcomes between the two sites may have related to
parallel improvement initiatives occurring at the comparator site
during the study period, including a sepsis improvement project
in the ED and an active deteriorating patients improvement
programme. It is also possible that the existence of a high-proﬁle
improvement initiative in its sister hospital improved AKI
awareness in BGH. Finally, we may have lacked statistical power
to detect subtle improvements in outcomes, if they existed. These
may have been limited to speciﬁc patient groups (e.g., patients
with severe AKI).
Nonetheless, our data are consistent with recent reports
suggesting some beneﬁts of e-alerting systems. A small rando-
mised study in China demonstrated that e-alerting alone
increased AKI recognition and specialist nephrology review when
applied to intensive care and specialist cardiovascular units.20 That
this might improve outcomes is supported by a Korean study,
which reported the impacts of an e-alert system which facilitated
nephrology consultation, comparing data from implementation to
historical controls in the same site. AKI detection improved,
nephrology consultations within 3 days increased, and the odds of
an AKI 2 or 3 event were reduced and of AKI recovery increased.
However, the baseline demographic characteristics of the two
groups in this study were profoundly different across a multitude
of domains.21 Two single-site before and after studies of AKI e-
alerts were conducted in England. The ﬁrst—an evaluation of a
complex intervention consisting of an AKI specialist team, a
‘Priority Care Checklist' and targeted education activities—was
associated with improved AKI detection, ﬂuid assessment and
drug assessment, and key general aspects of care. AKI incidence,
case length of stay and time to recovery all reduced. However, in
common with our research, it is unclear which component(s)
inﬂuenced the outcomes.22 The second study combined an e-alert
(telephoned to the ward, but visible to the outreach team) with a
protocol for patient management, staff education and a dedicated
outreach team. This resulted in reduction in AKI case mortality and
length of stay. However, the number of AKI cases detected rose
dramatically after the intervention (and continued to do so
thereafter), raising the possibility that these impacts were due to
the inclusion of patients at lower risk in the denominator group.
This would be supported by the fact that coding data (reliant on
case-record documentation) rather than laboratory data were
used for case ascertainment.23
A strength of our evaluation was the use of a comparator site—
the ﬁrst study of its kind to do so. The inclusion of this site
highlighted both the difﬁculty in disentangling the ‘active’
components of a complex intervention and the necessity of
comparator data to avoid erroneous conclusions about
intervention effectiveness. Additionally, we have clinically
reviewed all AKI cases ascertained for analysis using NHSEDA
and validated this process.
The limitations of our evaluation include the use of only one
intervention site, and the short time periods for data collection.
The evaluation design did not allow us to deﬁne (or control for)
any seasonal changes in outcome; the observed trends could
therefore be confounded by seasonal effects. Such effects are
known to occur: of 48,457 incident AKI alerts in the Welsh Health
Service, 90-day mortality was 28.5% in October–March vs. 25.5% in
April–September.24 A much longer period of pre-intervention data
collection would be required to conﬁrm this; future studies should
bear such effects in mind in their design. Additionally, the time-
series models we used do not adjust for differences in patient-
level variables between sites and time periods. The comparator
site hospital control group differed signiﬁcantly in baseline patient
characteristics; these probably related to the complex nature of
care at RFH that includes regional cardiac, liver, rheumatology,
respiratory, HIV and infectious diseases services as well as a
national amyloid service and tertiary vascular, urological cancer
and hepatobiliary surgical services; in particular, there was a much
higher prevalence of pre-existing renal disease. Our sensitivity
analysis controlled for the effects of some potential confounders
on renal recovery, and found similar results to our primary
analysis, but we cannot rule out that unmeasured confounders
may have inﬂuenced our ﬁndings. Additionally, although time to
in-application AKI recognition and virtual review by a specialist
was very rapid (median 11.5 min), we were not able to collect
comparable data from the pre-implementation phase as this
process is new to the care pathway we designed and implemen-
ted. The predeﬁned analysis of clinical impact resulted in multiple
tests for each outcome we considered, which increased the
theoretical risk of rejecting a true null hypothesis. Finally, our
initial power calculations did not account for the effect of alert
validation on case numbers; weekly case numbers were lower
than anticipated at the time we published the protocol.
We have therefore described the successful implementation of
a care pathway that enables a team of specialists to be alerted to
potential changes in hospitalised patients’ kidney function in real
time, rapidly review a curated set of relevant clinical data,
intervene proactively and remotely monitor and follow-up cases.
We have demonstrated that through such technology, in-
application specialist review of AKI cases can take place in
minutes. This care pathway has improved the timeliness and
reliability of key aspects of AKI care, but deﬁnitive conclusions
regarding the clinical impact of the pathway cannot be made at
this stage and are limited by the scope and nature of our
evaluation. Qualitative and economic analyses of the care pathway
are currently underway, the results of which will be published in
due course, as will data relating to the impact of the care pathway
as well as clinical outcomes for patients developing AKI during the
course of hospital admission. However, we believe that multi-site
evaluation, over longer periods, is required to comprehensively
assess the performance and impact on AKI outcomes in different
healthcare organisations. Any improvements must also be shown
to be of value to users and the wider hospital community, and to
be cost effective.
Such digitisation may not only improve delivery of existing AKI
care processes, but also enable delivery and evaluation of novel
interventions through clinical trials. Advances in machine learning
may enable AKI prediction ahead of time, fostering more
preventive and targeted therapy. Finally, while the effectiveness
of early deployment of specialists might not necessarily be
equivalent, key components of this approach may beneﬁt the
delivery of time-critical care pathways for other conditions. We
believe that any such digitisation must be clinically led and
patient-centred, and informed by multi-method evaluation of the
A. Connell et al.
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organisational, behavioural and technical components of the
intervention.
METHODS
Intervention and comparator sites
The pathway was implemented at the RFH, a large central London (UK)
tertiary referral hospital providing a range of acute services—including a
34-bed ICU and a comprehensive inpatient nephrology service. The
comparator site (which did not receive the digitally enabled care pathway)
—BGH—is a district general hospital providing acute care including a 21-
bed intensive care unit (ICU) providing acute renal replacement therapy
and liaison nephrology services. Similar arrangements for the early care of
AKI patients were in place at both sites prior to pathway implementation.
Both are part of the RFLFT.
The pre-implementation care pathway
Historically, both RFLFT sites had a multidisciplinary educational pro-
gramme on AKI prevention, recognition and care. AKI was usually
managed in its early stages by general acute care and various specialty
teams. Using desktop computers, ordering clinicians reviewed test results
including serum creatinine, usually in batches at the end of the working
day. Results suggestive of AKI were telephoned to the clinical area by
laboratory staff and a message placed on the results viewing system,
linking to online clinical guidelines. Specialist input into AKI management
could be requested through hospital pagers and telephone
communication.
The digitally enabled care pathway
Streams (DeepMind Technologies Ltd, London, UK) is a mobile application
deployed on iPhone Operating System (iOS)-enabled smartphones. It
processes relevant, routinely collected clinical and demographic data
through secure integration with existing information systems. Data
security is achieved through on-disk and in-ﬂight encryption, in
compliance with NHS Digital information security guidelines. It was ﬁrst
registered with the Medicines and Healthcare Products Regulatory Agency
(MRHA) as a Class I, non-measuring, non-sterile medical device on 30
August 2016.
During implementation, Streams analysed serum creatinine results
immediately and continuously, alerting the specialist clinical response
team to all potential AKI cases as deﬁned by the NHSEDA. Simultaneously,
a mobile electronic health record was provided which contained data
relevant to AKI management, including a historical trend view of serum
creatinine, current AKI stage, speciﬁc ﬂags for life-threatening AKI
complications, details of previous AKI episodes, demographic information
and past medical history (from coded Hospital Episode Statistics data).
Videos with detailed demonstrations of app functionality can be found on
the DeepMind Health Support website.25
A Streams ﬁlter excluded paediatric (aged <18 years) patients pre-
notiﬁcation. The RFH specialist clinical response team also excluded
patients who would not beneﬁt from the digitally enabled care pathway,
i.e., critical care and renal unit inpatients and known dialysis patients.
The specialist clinical response team (henceforth, the ‘AKI response
team’) comprised the existing nephrology and ‘patient-at-risk and
resuscitation’ (PARRT) teams. The nephrology team comprised a renal
consultant and a speciality registrar. Both received all AKI notiﬁcations. A
renal registrar was onsite 24 h (working in shifts) a day and was usually the
ﬁrst responder. The consultant could triage alerts through secure, remote
access if offsite, providing supervision and subsequent clinical review
where needed but did not review alerts after midnight unless contacted.
The PARRT team are Clinical Nurse Specialists who review at-risk or
deteriorating inpatients, 24 h a day, again through shift cover. They
received alerts on NHSEDA-deﬁned AKI stages 2 and 3. Through Streams,
the AKI response team triaged cases, communicated with other team
members and documented clinical reviews and actions undertaken. These
digital entries were visible for any subsequent alerts produced for the
same patient. Relevant contacts and clinical guidance were available on
Streams phones.
Case review within 2 h was suggested for all alerts, although the
response team could prioritise patients according to the information
available in Streams. Patients with life-threatening complications or
deemed at high risk were reviewed immediately. The response team used
a care protocol based on existing best practice guidelines17,26
(Supplementary Fig. 2). This was annotated and entered into the patient’s
notes alongside an advisory sticker for key nursing actions (Supplementary
Fig. 3). In general, the response team would support the team primarily
responsible for the patient, although the nephrology team would
occasionally take over patient care. Streams allowed the response team
to monitor AKI recovery remotely in-application. Re-alerting for AKI that
had not recovered was enabled 48 h after the ﬁrst alert. Worsening of AKI
stage at any time resulted in a further notiﬁcation. Secondary response
team reviews were undertaken for repeat alerts according to clinical
judgement. A diagram outlining the pre- and post-intervention care
pathways is provided in Supplementary Fig. 4; while clinical guidelines and
specialist response teams existed prior to the new care pathway,
implementation aimed to improve the reliability and speed at which AKI
recognition and appropriate specialist review occurred.
Implementation
Prior to deployment, a secure data processing architecture was developed,
tested and integrated with existing RFH information systems. The Streams
application was developed iteratively, through consultation with the AKI
response team. This included formal scoping of user requirements,
collaborative workshops with designers and clinicians and user experience
testing of the application with mock data. Streams users attended training
events and accessed a video users’ guide to both the application and the
clinical pathway. During a 16-week pathway optimisation period (January
to May 2017), feedback was gathered from the response team and key
pathway adjustments made. The optimised care pathway was deployed
continuously at RFH from 8 May to 10 September 2017 (18 weeks), during
which time the response team comprised 47 users (11 consultants,
21 specialist registrars and 15 PARRT nurses) using six iPhones (Apple Inc.,
Cupertino, USA).
Data collection
At both sites, sociodemographic and clinical outcome data from the
intervention period (May to September 2017) were compared to data from
a pre-deployment phase (May 2016 to January 2017). These data were
extracted from the database supporting Streams, and from RFLFT hospital
databases. The presence of individual co-morbidities and overall patient-
speciﬁc Charlson comorbidity index score (which categorises co-
morbidities based on the International Classiﬁcation of Diseases (ICD)
diagnosis codes in administrative data) were derived as per Thygesen
et al.27 Indices of Multiple Deprivation (IMD)—a measure combining seven
domains (income/employment/living environment/health/education skills
and training deprivation and disability, barriers to housing and services,
and crime) into a single deprivation score for a small area—were derived
by cross-referencing patient postcodes with the UK Government’s Indices
of Deprivation 2015 dataset.28 Patients were sorted into quintiles of
deprivation (quintile 1 least deprived, quintile 5 most deprived).
All process data were collected as part of an existing RFH project
examining processes of care for AKI patients in ED. These data were
collected over the two 9-month periods before and after the introduction
of the new care pathway (January to September 2016 and 2017,
respectively). For each month, 30 clinically validated AKI alerts were
selected at random, split evenly across all three stages of AKI severity.
Patient records were viewed by a team of RFLFT doctors-in-training
unconnected to the project. Times for hospital arrival, AKI recognition
(where recognition occurred) and treatment of each principal AKI cause
were recorded on a proforma. Recognition was deﬁned as the time at
which AKI presence was documented in the patient’s notes. The time at
which nephrotoxicity was addressed was deﬁned that at which a physician
documented the decision to withhold or adjust the dose of nephrotoxic
medication. Times for the treatment of sepsis, hypovolaemia, obstruction
and primary renal disease were deﬁned as those recorded in drug chart or
procedural documentation. Discrepancies or queries about the cases or
data collection methods raised by data collectors were discussed with one
author (O.S.-A.), who also reviewed every collected process of care data
point. Data collected, and their sources, are detailed in Table 4.
Evaluation of impacts
The study design protocol has been previously published.29 The impact of
the optimised care pathway on clinical outcomes was assessed by
comparing data from the deployment phase (May to September 2017) to
data from a pre-deployment phase (May 2016 to January 2017) in both the
intervention and comparator sites. The primary outcome was recovery of
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renal function, deﬁned as a return to a creatinine level within 120% of the
baseline (itself deﬁned by NHSEDA) prior to hospital discharge. Predeﬁned
endpoints reﬂecting secondary processes of care and clinical outcomes are
outlined in Table 4.
At both sites, NHSEDA was used to identify potential AKI cases. Because
the NHSEDA can produce false positives,30 two authors (A.C. and C.L.)
clinically validated all AKI alerts produced from all time periods at both
hospital sites. Only clinician-conﬁrmed episodes of AKI were included in
the analysis. In this paper we report the outcomes of patients presenting
acutely to RFH and BGH hospital ED who had AKI on arrival during the pre-
deployment and deployment phases (Fig. 3).
Statistical analysis
All data were pseudonymised prior to transfer from the RFLFT to University
College London (UCL) for analysis. All analyses were performed using R,
version 3.4.3.31 Segmented regression analysis was used to estimate the
effect of the intervention on our primary outcome—recovery of renal
function prior to hospital discharge—and on ﬁve secondary outcome
measures: mortality within 30 days of alert; progression of AKI stage;
transfer to renal/intensive care units during admission; readmission within
30 days of discharge; and dependence on renal replacement therapy
30 days after discharge. All outcomes were measured as weekly
proportions. Binomial regression models with a logit link were used. The
variable ‘intervention' was coded 1 for the time period after the
intervention (May to September 2017) and 0 for the pre-intervention time
period (May 2016 to January 2017). The intervention and comparator sites
were coded 1 and 0 respectively. The variable ‘time' denoted the week
number, with 1 denoting the ﬁrst week of the intervention period, and
weeks in the pre-intervention period being denoted by negative numbers.
The statistical model used was:
logitðyÞ ¼ β0 þ β1intþ β2timeþ β3siteþ β4int ´ time
þβ5int ´ siteþ β6time´ siteþ β7int ´ time ´ site
where y denotes the proportion of interest, int, time and site denote the
variables intervention, time and site, respectively (as deﬁned above), and
β0, …, β7 are the coefﬁcients to be estimated. We focus on four effects of
interest. Two coefﬁcients evaluate the evidence for a step change in the
outcome due to the intervention: the effect of intervention estimates the
step change in outcome at the start of the intervention period at RFH. The
interaction site × intervention estimates the difference-in-difference in the
step change between the two hospital sites. Two further effects of interest
Table 4. Deﬁnitions of each outcome and sources of data collected
Data category Measure Deﬁnition Source of data
Sociodemographic Age Age in years at the time of alert HL7 data aggregated within the
Streams data processor
Gender Gender codes used in NHS Data Dictionary36 HL7 data aggregated within the
Streams data processor
Ethnicity Ethnicity category codes used in NHS Data Dictionary36 HL7 data aggregated within the
Streams data processor
Co-morbid disease Presence of individual Charlson index co-morbidities and
overall Charlson score
HL7 data aggregated within the
Streams data processor
Deprivation Index of multiple deprivation Ministry of Housing,
Communities &
Local Government database
Clinical outcomes Recovery of renal function Return to <120% index creatinine (as deﬁned by
NHSEDA) by the time of hospital discharge
HL7 data aggregated within the
Streams data processor
Time to recovery of renal
function
The time from AKI alert to recovery of renal function
(<120% index creatinine).
HL7 data aggregated within the
Streams data processor
Mortality Death in 30 days following AKI alert HL7 data aggregated within the
Streams data processor
Progression of AKI stage Movement between AKI severity classes following AKI
alert and prior to hospital discharge
HL7 data aggregated within the
Streams data processor
Admission to high acuity or
specialist renal inpatient bed
Admission to acute kidney unit (AKU) or other renal
ward, high dependency unit (HDU) or intensive care unit
(ICU) during index admission
HL7 data aggregated within the
Streams data processor
Requirement for long-term renal
replacement therapy
Use of haemoﬁltration, haemodiaﬁltration,
haemodialysis or peritoneal dialysis in 30 days following
hospital discharge date
RFH Nephrology Clinical
Information Management System
Length of stay Time from AKI alert to hospital discharge HL7 data aggregated within the
Streams data processor
Readmission to hospital Readmission to hospital in 30 days following index
admission discharge date
HL7 data aggregated within the
Streams data processor
Processes of care Time to generation of AKI alert Time (in min) from entry to ED to the alert generation HL7 data aggregated within the
Streams data processor
Time to AKI alert review Time (min) from alert generation to alert viewing HL7 data aggregated within the
Streams data processor
Time to recognition of AKI Time (min) of documentation of recognition of AKI (in
written notes)
Electronic/Paper note review
Time to treatment Time of documentation of delivery of antibiotics for
sepsis, delivery of ﬂuid for hypovolaemia, relief of
obstruction, adjudication of nephrotoxins, and deﬁnitive
treatment for parenchymal kidney disease
Electronic/Paper note review
Health Level 7 (HL7) messages are used to transfer information between different healthcare IT systems
AKI acute kidney injury, NHS National Health Service, NHSEDA NHS Early Detection Algorithm, ED emergency department, RFH Royal Free Hospital
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evaluate the evidence for a change in temporal trend in the outcome due
to the intervention: the interaction time × intervention estimates of the
difference in outcome trend over time between the intervention period
and the pre-intervention period at RFL; the three-way interaction time ×
site × intervention estimates the difference-in-difference in the trend
between the sites. All models were checked for autocorrelation by
inspecting the autocorrelation function up to lag 15; no signiﬁcant
autocorrelation was found. At the point of protocol publication, it was not
anticipated that we would be able to collect patient-level data relating to
sociodemographics and co-morbid disease. To examine the robustness of
our primary outcome analysis, we performed a sensitivity analysis using
binary logistic regression that used the same model as above, except that
the outcome was deﬁned at the patient level and that patient-level
characteristics were included as covariates. Covariates used for this model
were age, sex, ethnicity category, index of multiple deprivation, AKI alert
level, the presence of complications at the time of alert, and the presence
of individual Charlson Score co-morbidities. The addition of these
covariates allowed us to adjust for any differences in casemix between
sites, and within sites over time.
The time to creatinine recovery (where this occurred by hospital
discharge) was analysed using the Wilcoxon rank-sum test. A competing
risk analysis was performed to estimate the effect of the intervention on
the length of hospital stay to allow for the effects of in-hospital death on
this outcome.32 A survival analysis was performed to determine the effect
of the intervention on the time to recognition of AKI. All other processes of
care and sociodemographic variables were analysed using the Wilcoxon
rank-sum and chi-squared tests as appropriate.
In order to assess the reliability of case validation, 500 alerts selected
randomly from all time periods and all sites were validated a second time.
Cohen’s kappa coefﬁcient was used to determine intra- and inter-rater
reliability (Supplementary Table 1).
Ethical approval
The digitally enabled care pathway constituted a new standard service at
RFH. The UCL Joint Research Ofﬁce reviewed the study protocol and
judged that the project fell under the remit of service evaluation, as per
guidance from the NHS Health Research Authority.33 As such, no patient
consent was required. The evaluation was registered with the RFH Audit
Lead and Medical Director. An independent Data Monitoring Committee
(which included a patient member) reviewed all analyses prior to
preparation for publication. A full list of Committee members is provided
as Supplementary Material.
DeepMind was acquired by Google in 2014 and is now part of the
Alphabet group. The deployment of Streams at RFH was the subject of an
investigation by the Information Commissioner’s Ofﬁce in 2017. RFH has
since published an audit completed to comply with undertakings following
this investigation.34 In November 2018, it was announced that the Streams
team will be joining Google as part of a wider health effort.35
Reporting Summary
Further information on experimental design is available in the Nature
Research Reporting Summary linked to this paper.
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